The emerging therapeutic role of antibody mixtures

Expert Opinion on Biological Therapy

Volumn 13, Issue 7, 2013, Pages 953-958

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antibody engineering; Antibody manufacturing; Antibody mixture; Bispecific antibodies; CL184; Combotox; Rozrolimupab; Sym004; Therapeutic antibodies; XOMA 3AB

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALEMTUZUMAB; BISPECIFIC ANTIBODY; BOTULINUM TOXIN A; CETUXIMAB; CL 184; CYCLOPHOSPHAMIDE; FLUDARABINE; HEMOGLOBIN; LUMILIXIMAB; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RITUXIMAB; ROZROLIMUPAB; SYM 004; UNCLASSIFIED DRUG; XOMA 3AB;

ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; APOPTOSIS; BIOREACTOR; BOTULISM; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVOR; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; COOMBS TEST; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VITRO STUDY; LEUKEMIA RELAPSE; POST EXPOSURE PROPHYLAXIS; RABIES; RABIES VIRUS; REVIEW; SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; DRUG DELIVERY SYSTEMS; EPITOPES; HUMANS; NEOPLASMS;

EID: 84878912190     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.799133     Document Type: Review

References (40)

1. Li F, Vijayasankaran N, Shen AY, et al. Cell culture processes for monoclonal antibody production. MAbs 2010;2:466-79
2. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007;12:1084-95
3. Robak T. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncol 2013;9(1):69-91
4. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37
5. Fagète S, Fischer N. Smarter drugs: a focus on pan-specific monoclonal antibodies. BioDrugs 2011;25:357-64
6. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther 2010;12:340-9
7. Choi BD, Kuan CT, Cai M, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA 2013;110:270-5
8. Fuentes G, Scaltriti M, Baselga J, et al. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011;13:R54
9. Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 2013;27:35-53
10. Rasmussen SK, Næsted H, Müller C, et al. Recombinant antibody mixtures: production strategies and cost considerations. Arch Biochem Biophys 2012;526:139-45
11. Byrd JC, Kipps TJ, Flinn IW, et al. Phase = study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115:489-95
12. Robak T. Improving FCR immunochemotherapy in CLL. Blood 2010;115:437-8
13. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110-18
14. Gutiérrez-Aguirre CH, Cantu-Rodríguez OG, Borjas-Almaguer OD, et al. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica 2012;97:717-22
15. Raju TS. Assessing Fc Glycan Heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC. Methods Mol Biol 2013;988:169-80
16. Yusibov V, Streatfield SJ, Kushnir N, et al. Hybrid viral vectors for vaccine and antibody production in plants. Curr Pharm Des 2013; Epub ahead of print
17. Rasmussen SK, Nielsen LS, Müller C, et al. Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes. BMC Proc 2011;5(Suppl 8):O2
18. Frandsen TP, Naested H, Rasmussen SK, et al. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011;108:2171-81
19. Skartved NJ, Jacobsen HJ, Pedersen MW, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011;17:5962-72
20. Pedersen MW, Jacobsen HJ, Koefoed K, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97
21. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6:1302-13
22. Schindler J, Gajavelli S, Ravandi F, et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011;15:471-6
23. Herrera L, Bostrom B, Gore L, et al. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41
24. Vallera DA, Chen H, Sicheneder AR, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33:1233-42
25. Bakker AB, Marissen WE, Kramer RA, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005;79:9062-8
26. Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008;26:5922-7
27. Kostense S, Moore S, Companjen A, et al. Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples. Antimicrob Agents Chemother 2012;56:3524-30
28. Meyer K, Ng H, Parman T, et al. Nonclinical safety evaluation of XOMA 3AB, a novel triple monoclonal antibody drug product targeting botulinum toxin type A, in Sprague-Dawley Rats. Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Meeting; 10 - 12 January 2011; Washington
29. Teshima G, Li MX, Danishmand R, et al. Separation of oxidized variants of a monoclonal antibody by anion-exchange. J Chromatogr A 2011;1218:2091-7
30. Meng Q, Li M, Silberg MA, et al. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem 2012;421:351-61
31. Nielsen LS, Baer A, Müller C, et al. Single-batch production of recombinant human polyclonal antibodies. Mol Biotechnol 2010;45:257-66
32. Pedersen MW, Jacobsen HJ, Koefoed K, et al. Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97
33. Koefoed K, Steinaa L, Søderberg JN, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011;3:584-95
34. Dechant M, Weisner W, Berger S, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008;68:4998-5003
35. Andersen PS, Haahr-Hansen M, Coljee VW, et al. Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. Mol Immunol 2007;44:412-22
36. Wiberg FC, Rasmussen SK, Frandsen TP, et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006;94:396-405
37. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010;12:734-40
38. Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012;120:3670-6
39. de Kruif J, Kramer A, Nijhuis R, et al. Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng 2010;106:741-50
40. Rosati S, Thompson NJ, Barendregt A, et al. Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry. Anal Chem 2012;84:7227-32